Toronto, Ontario — May 7, 2026 — Leads & Copy — Red Light Holland Corp. has confirmed additional shipments of Filament Health’s PEX010 to support research and compassionate use programs across North America. The shipments follow Red Light’s acquisition of Filament Health Corp. on April 30, 2026, which expanded its capabilities in pharmaceutical-grade manufacturing, regulatory affairs, and clinical research.
The additional shipments of Filament Health’s PEX010 support the following:
-University of Calgary (“UCalgary”) – Second shipments in support of ongoing clinical studies in Alcohol Use Disorder and Persistent Post-Concussion Symptoms.
-University of California, San Francisco (“UCSF”) – A second shipment delivered for the UCSF study entitled “A Double-blinded, Active Placebo-Controlled, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People with Chronic Low Back Pain”, to enable continued research collaborations in the United States.
-A first-time shipment supporting a clinical study at a Canadian academic institution, further expanding PEX010’s footprint within Canada’s psychedelic research program.
-Compassionate Use Program – Multiple shipments of PEX010 to support patients approved through the compassionate use program, reflecting growing physician and patient demand for pharmaceutical-grade, naturally-derived psilocybin in real-world therapeutic settings.
-3rd party lab – A shipment of PEX010 to Filament’s contracted third-party analytical laboratory, supporting ongoing quality control, analytical testing, and GMP compliance activities that underpin Filament’s manufacturing and supply chain infrastructure.
PEX010 is Filament Health’s botanical psilocybin drug candidate. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.
Todd Shapiro, CEO and Director of Red Light, stated that the shipments reflect growing demand for pharmaceutical-grade, naturally derived psilocybin and reinforce the expanding role of Filament Health’s PEX010. He added that it supports academic, clinical, and compassionate use initiatives and strengthens operational and quality systems for reliable global supply.
Red Light Holland is focused on expanding naturally occurring drug development, understanding of psilocybin use and consumer experiences, through consensual data collection and R&D initiatives. The company also conducts commercial activities across Europe and North America.
Filament Health is a clinical-stage natural psychedelic drug development company whose mission is to see them in the hands of everyone who needs them as soon as possible.
On April 30, 2026, Red Light completed its acquisition of Filament Health Corp., including its portfolio of 76 issued patents across 15 patent families and its lead drug candidate, PEX010.
Source: Red Light Holland
